Visit COVID-19 resources

[Skip to Content]


The British Ophthalmological Surveillance Unit restart

After a six month break, The British Ophthalmological Surveillance Unit has restarted case ascertainment from November 2020, recommencing the yellow card reporting system with the five studies that were already running. BOSU: Current Studies on the Yellow Card Study Lead investigator Hydroxychloroquine Retinopathy Imran Yusuf, Oxford Unexplained visual loss following removal of silicone oil Jonathan

The RED Trust Bursary is open for applications from Ophthalmologists in Training

The British Ophthalmological Surveillance Unit is advertising the RED Trust Bursary open for applications from Ophthalmologists in Training. With the kind support from The Research in Eye Disease Trust, the BOSU is offering a research bursary of £6000 to support an ophthalmologist in training to undertake an epidemiological study of a rare eye condition through

The Royal College of Ophthalmologists welcomes Senedd inquiry focussing on management of ophthalmic outpatients across Wales

The Royal College of Ophthalmologists (RCOphth) recently took the opportunity to provide a statement as part of The Royal College of Physicians response to the Welsh Assembly (Senedd) Public Accounts Committee inquiry into the management of follow up outpatients across Wales. It is important that the committee recognises the very real risk of loss of

Look out for new 2018 BOSU study on sight loss and deterioration caused by delay in ophthalmic review or treatment

Last year, RCOphth published research from a British Ophthalmological Surveillance Unit (BOSU) study conducted during 2015 -16. The research found that up to 14 patients per month suffered preventable loss of vision through hospital initiated delays, with a likelihood of the true rate being between 16 and 22 cases per month. Since publication in Eye (Vol 31,

BOSU News: No 32. Spring 2018

Welcome to the first BOSU News for 2018. This year marks our coming of age as we enter our 21st year of rare disease surveillance in the UK. In this issue we have summarised the results of our 20-year evaluation. The most noteworthy of which are the high levels of utilisation of study findings and